Description

The Hepatic Fibrosis Test YRA317 // YRA321 offers a crucial advantage in the early detection and management of liver fibrosis. This innovative test is vital for identifying liver damage at an initial stage, providing a window of opportunity to reverse fibrosis or halt its progression. Compatible with Chemiluminescence Immunoassay Analyzers YR06389 and YR06390, this test is essential for healthcare professionals aiming to enhance patient outcomes and quality of life through timely intervention.

Market Price

The market price for hepatic fibrosis tests varies depending on the supplier and quantity purchased. Typically, this type of diagnostic test ranges from $200 to $500 per kit, depending on the specific reagents and technology included. For the best pricing and to secure a quote, we recommend using the Kalstein Plus platform to generate an automatic price estimation.

Frequently Asked Questions

What parameters does the Hepatic Fibrosis Test YRA317 // YRA321 measure? This test measures PIIINP, CIV, LN, HA, and CG to provide a comprehensive assessment of liver fibrosis.

How should the test kits be stored? The kits should be stored at temperatures between 2-8°C to maintain their efficacy.

Advantages and Disadvantages

The primary advantage of the Hepatic Fibrosis Test YRA317 // YRA321 is its capability to detect liver fibrosis at an early stage, allowing for effective management and treatment. Additionally, its compatibility with advanced CLIA technology ensures precise results. A potential drawback is the necessity of specific equipment for testing, which might not be accessible in all healthcare facilities.

Field Use

In practical scenarios, the Hepatic Fibrosis Test YRA317 // YRA321 is utilized within clinical laboratories equipped with Chemiluminescence Immunoassay Analyzers. The workflow involves sample processing and analysis, with results aiding clinicians in making informed treatment decisions for liver fibrosis management.

Recommendations

For optimal performance, ensure that all testing personnel are adequately trained in using CLIA technology. Regular calibration and maintenance of analyzers in compliance with manufacturer guidelines will enhance the longevity and accuracy of test results. To facilitate easy procurement, consider joining the Kalstein Plus platform for efficient order management.

Features

• Early detection of liver fibrosis for proactive treatment.
• Compatibility with YR06389 and YR06390 Chemiluminescence Immunoassay Analyzers.
• Comprehensive panel measuring key indicators of liver fibrosis.
• Highly accurate results utilizing CLIA technology.
• CE, ISO13485, FSC certified ensuring quality and safety.

Technical Specifications